Early studies of ATAD2 in cancers, considering a series of cancer-related transcription factors, such as Myc, E2F, or androgen and oestrogen receptors, led previous investigators to define ATAD2 as a transcriptional co-activator (Boussouar et al., 2013). This evidence concerns the gene MYC and cancer.